Information Center
Xinkang has been selected as one of the top 10 antibody innovation drug companies with the most development potential.
Release time:
2021-10-08 16:01
2021Year9Month28On the day, Xinkanghe Biopharmaceutical is honored to be selected for the "Touch Technology Annual List"2021as the most promising antibody innovative drug company. This list was grandly released at the third Asian Biopharmaceutical Innovation Summit hosted by Touch Technology and co-organized by Qingjie Capital.BIC2021The list comprehensively covers outstanding companies, investment institutions, and investors in the biopharmaceutical investment industry. Xinkanghe's successful selection is another recognition of the company's strength and development potential in the pharmaceutical industry.
Since its establishment six years ago, Xinkanghe Biopharmaceutical has focused on the development of first-in-class antibody drugs in the fields of autoimmune diseases and tumors.(First in class)With a deep understanding of cutting-edge immunology research and rapid clinical translation, as well as the efficient promotion of a professional R&D team, the company has continuously achieved milestone results at various project stages. The company's globally first innovative drug project for treating inflammation and autoimmune diseases—XKH001(IL25antibody),已经在今年7月获得了美国FDA的临床批准，8月完成了中国CDE的临床申报。从创新技术平台的搭建运营到研发各关键环节的开发和验证，从国内首创药的临床申报到到全球首创药物的中美双报，鑫康合一步一个脚印，坚实地做好每一个研发环节，秉承“创新、精准、优质、专注”的研发理念，通过在临床转化医学的不断探索和投入，在免疫药物靶点和适应症创新上均处于国际前沿，国内领先地位。
展望未来，鑫康合将会继续加大各方面资源的整合，拓展研发团队，不断建立新的技术平台，提升公司新药开发的能力。在快速推进现有项目的前提下，深入研究和挖掘免疫通路的新靶点，以临床需求为导向，提高临床转化效率，期待早日为全球患者提供更加安全，有效的创新药物。
Antibody innovative drug companies
Related News
Beijing Address: A203, Zhongguancun Biomedical Park, No.5, Development Road, Haidian District, Beijing
Zhejiang Address: Floor 8, Building 7, Dongsheng Huigu, 1299 Kehai Avenue, Keqiao District, Shaoxing City, Zhejiang Province
Contact Phone:010-82176552
E-mail:hr@kanovabiopharma.com